复方樟柳碱注射液治疗糖尿病性缺血性视神经病变的疗效观察

Effect of compound anisondine on diabetic ischemic optic neuropathy

目的探讨复方樟柳碱(CA)治疗糖尿病性缺血性视神经病变的疗效及安全性。方法糖尿病性缺血性视神经病变患者112例198只眼,58例97只眼予常规治疗,54例101只眼予常规联合CA治疗,疗程均为6周。所有患者根据眼底情况决定是否施行视网膜激光光凝,比较常规治疗与联合CA治疗患者视力、视野、视网膜神经纤维层厚度的变化情况,并观察CA治疗的安全性。结果未行视网膜激光光凝的患者,常规治疗和联合CA治疗的有效率分别为72.92%和98.04%;施行视网膜激光光凝患者,常规治疗和联合CA治疗的有效率分别为65.30%和96.00%,不同情况下两种治疗方法的疗效差异均有统计学意义(P<0.05),常规联合CA治疗的效果更好,且未见不良反应发生。结论复方樟柳碱治疗糖尿病性缺血性视神经病变有效。

OBJECTIVE To investigate the efficacy and safety of the compound anisondine （CA）in treating diabetic ischemic optic neuropathy. METH- ODS One hundred and eleven cases （198 eyes）with diabetic ischemic optic neuropathy were divided into two groups according to the need of photocoagulation, and each group was randomly divided into normal treatment group and CA treatment group.Patients in normal treatment group were treated by conventional way and those in CA treatment group were treated with CA plus conventional treatment for 6 weeks. Three months later, the vision, visual field changes and OCT different groups were inspected and the safety was evaluated. RESULTS The effective rate was 72.92% in normal treatment group and 98.04% in CA treatment group （P〈0.05） in nonphotocoagulation group,and 65.30% in normal treatment group and 96.00% in CA treatment group （P〈0.05） in photocoagulation group. The general effective rate of later was higher than the former （P〈0.05）. CONCLUSIONS Compound anisondine was an effective and safe way to treat diabetic ischemic optic neuropathy, which is worth widely applying in clinical practice.